Background: Induction treatment of mild-to-moderate Crohn's disease is controversial. Purpose: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn's disease. Data sources: We identified randomized controlled trials from existing Cochrane reviews and an updated literature search in Medline, EMBASE, and CENTRAL to November 2015.
mesalamine with one study showing that 90% of gastroenterologists surveyed prescribed mesalamine alone or in combination for the treatment of active Crohn's disease. 8 A network meta-analysis (NMA) includes both direct (head-to-head) and indirect evidence (where treatments have been evaluated in separate trials against a common comparator, e.g., placebo); this type of analysis allows for comparisons between treatments where there is minimal evidence. A previous NMA confirmed the lack of effectiveness of mesalamine as an induction agent in Crohn's disease. 9 However, the effectiveness of mesalamine may be dependent on the definition of the outcome studied and the doses compared when pooling across randomized controlled trials (RCTs). Therefore, we performed an NMA of mesalamine, sulfasalazine, corticosteroids, and budesonide used for the induction of remission in active Crohn's disease.
METHODS
We conducted a systematic review and NMA of RCTs that examined the use of aminosalicylates (mesalamine, olsalazine, and balsalazide), sulfasalazine, corticosteroids, or budesonide to induce remission in adults ($18 yr old) with Crohn's disease.
Literature Search
RCTs were identified from existing Cochrane reviews. 5, 6, 10 We updated database searches in MEDLINE and EMBASE and Cochrane CENTRAL Registry of Controlled Trials from the date of the earliest search in the Cochrane reviews (January 2004) until November 2015. No language restrictions were used. A full description of search terms for MEDLINE, EMBASE, and CENTRAL can be found in Appendix 1, Supplemental Digital Content 1, http://links.lww.com/IBD/B451.
We supplemented the database search with a hand search of the Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Specialized Trial Register (November 2015) to identify any RCTs published since the search performed for the Cochrane reviews. We searched www.clinicaltrials.gov for ongoing or unpublished trials using the search terms "(mesalamine or sulfasalazine or steroid or prednisone) and Crohn's disease" (November 2015) . After the identification of all trials, experts in the field determined (R.P., C.H.S., S.G., and G.G.K.) if there were any relevant articles that were missed, including any ongoing or unpublished trials.
Study Selection
Trained reviewers, working in pairs, (S.C., M.E.K., and R.H.) screened the abstracts and titles of articles obtained using the above search strategy. Any disagreements were resolved by consensus. We included RCTs that compared mesalamine, sulfasalazine, budesonide, and corticosteroids with placebo or each other in adults ($18 years old) with Crohn's disease. The primary outcome was the induction of remission, from a study period of 8 to 17 weeks, defined using a standard definition of clinical remission (Crohn's Disease Activity Index, CDAI ,150). We excluded studies of combination therapy (e.g., mesalamine versus mesalamine + corticosteroids) and those that evaluated postoperative remission (see Appendix Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B451).
Data Extraction
Data were extracted independently by trained reviewers (S.C., M.E.K., and R.H.). A data extraction tool was used to capture patient characteristics, study definition of active disease and remission, type of medication and dose, the comparator, the number of patients in each trial, the proportion of patients in remission at the end of the study, and the total number of study participants withdrawing due to adverse events (WDAEs). All outcomes were extracted based on an intention-to-treat analysis.
Risk of Bias
Study quality was assessed independently by trained reviewers (S.C., M.E.K., and R.H.) using the tool published by the Cochrane Collaboration. 11 This tool incorporates the following criteria: random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting of outcomes. Any disagreements were resolved by consensus.
Network Meta-analysis
We performed an NMA to evaluate the comparative effectiveness of medications to induce remission and their safety as measured by WDAEs. Studies using mesalamine and budesonide were stratified into high and low doses; low-dose mesalamine was classified as ,2.4 g/d, high-dose mesalamine $2.4 g/d, lowdose budesonide #6 mg/d, and high-dose budesonide .6 mg/d. Doses of corticosteroids and sulfasalazine were not stratified. For each pairwise comparison, we estimated the odds ratios (ORs) with a 95% credible interval (CrI) and the probability of superiority using a Bayesian random-effects model. A 95% CrI in a Bayesian analysis is the range in which there is a 95% probability that the true common treatment effect lies. A treatment was considered superior (or inferior) to another if the 2-sided 95% CrI of the OR excluded 1, which equates to a 97.5% probability that the treatment is superior. We also calculated the rank ordering of the treatments for the induction of remission.
The analysis was performed using rjags package version 4-6 running Just Another Gibbs Sampler (JAGS) version 4.2.0 with R software version 2.15.2 (www.r-project.org). The JAGS code for the Bayesian NMA has been published and is provided in Appendix 2, Supplemental Digital Content 1, http://links.lww.com/IBD/B451. 12 Uninformative previous probability distributions were used for all variables in the Bayesian analysis. All chains were run with 10,000 burn-in iterations followed by 10,000 monitoring iterations. Convergence was tested by running 3 chains, observing trace plots and using Gelman-Rubin-Brooke statistics.
Comparison with Direct Effects and Assessment of Consistency of the Evidence
We compared the results from the NMA (including direct and indirect comparisons) to traditional meta-analyses (including only direct comparisons). Random-effects models were fitted using STATA 13.1 and were used to pool ORs with their corresponding 95% confidence intervals (CIs). An I 2 and Cochran Q statistic were calculated to assess for statistical heterogeneity between RCTs that examined the induction of remission in Crohn's disease.
Additionally, where both indirect and direct evidence were available, we conducted "node-splitting" analyses using the methods of Dias et al to calculate both the direct and indirect evidence separately. 13 These node-splitting analyses estimate the indirect evidence by removing all direct head-to-head comparisons from the network and rerunning the NMA model. We calculated the P-value as a statistical measure of inconsistency. 14 The P-value can be interpreted as the probability that the direct and indirect evidence are the same, such that lower values indicate a greater probability that there is inconsistency between the direct and indirect evidence. 14 All node-splitting analyses were performed using the gemtc package version 0.8.1 in R Statistical Software running JAGS version 4.2.0.
Sensitivity Analyses
We performed the following sensitivity analyses: (1) stratifying doses into 3 levels for mesalamine (,2 g, 2-4 g, and .4 g) and budesonide (3 or 6 mg, 9 mg, and 15 or 18 mg), similar to a previous NMA 9 ; (2) removing the stratification of low and high doses of mesalamine and budesonide; (3) restricting the RCTs to those who recruited patients with Crohn's disease with an enrollment CDAI score between 150 and 450; and (4) removing RCTs of sulfasalazine and corticosteroids from the analysis.
RESULTS

Description of Studies
We included 22 RCTs with 2968 patients that evaluated mesalamine/sulfasalazine, [15] [16] [17] [18] [19] [20] [21] [22] budesonide, 20, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] or corticosteroids 17, 19, 24, 25, 27, 28, [30] [31] [32] [33] [34] (Fig. 1) . The characteristics of the included trials are outlined in Figure 2 . The included studies primarily compared treatments with placebo [15] [16] [17] [18] [19] 21, 23, 26, 29 with head-to-head trials of budesonide to mesalamine, 20, 22 budesonide to steroids, 24, 25, 27, 28, 30, 31 and mesalamine to steroids [32] [33] [34] ; 2 studies were multiarm trials that compared sulfasalazine, corticosteroids, and placebo 17, 19 (Fig. 2) .
Risk of Bias
The risk of bias assessment is outlined in Appendix Table 2 , Supplemental Digital Content 1, http://links.lww.com/IBD/B451. One study was at a high risk of bias because it was an open-label study (failed to mask). 30 Three studies had clear allocation concealment. 17, 19, 26 Eight studies were rated as "unclear" for random sequence generation. [15] [16] [17] 19, [30] [31] [32] [33] Network Meta-analysis
Results from the NMA are reported in Table 2 . Corticosteroids (OR ¼ 3.64; 95% CrI: 2.16-6.19), high-dose budesonide (OR ¼ 2.99; 95% CrI: 1.83-4.90), and high-dose mesalamine (OR ¼ 1.87; 95% CrI: 1.14-3.15) were significantly superior to placebo to induce remission. Corticosteroids were the highest ranked treatment, followed by high-dose budesonide and highdose mesalamine (see Appendix Table 3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B451). Sulfasalazine was not superior to placebo (OR ¼ 1.50; 95% CrI: 0.71-3.12). High-dose budesonide and corticosteroids were significantly superior to low-dose mesalamine; in addition, corticosteroids were significantly superior to sulfasalazine, and low-dose budesonide (Table 2) . Corticosteroids were also superior to high-dose mesalamine with an OR of 1.95 (95% CrI: 1.14-3.25). Traditional Table 2) . WDAEs were not different between study drugs and placebo, nor between comparator drugs (Table 3) . Though, corticosteroids had a 93% and 90% higher probability of WDAEs as compared to budesonide and high-dose mesalamine, respectively (Table 3) .
Sensitivity Analyses
When the data were stratified based on 3 dose levels, 2-4 g mesalamine (OR: 1.74; 95% CrI: 1.04-3.12), 9 (Table 3) . High dose mesalamine was not superior to placebo (OR: 1.55; 95% CI: 0.80-3.11) ( Table 3) . We did not detect any statistical evidence of inconsistency between the direct and indirect evidence in the node-splitting analyses (Table 4) . Comparisons for the direct treatment effects were homogeneous except for the comparison of high-dose mesalamine with highdose budesonide that was heterogeneous.
CONCLUSION
Clinical practice guidelines have recommended the use of corticosteroids or budesonide in patients with mild-to-moderate Crohn's disease. Our NMA, in conjunction with previous metaanalyses, confirms that both budesonide and corticosteroids are effective induction agents. 36 Importantly, corticosteroids were not shown to be superior to budesonide. Budesonide was designed as a steroid with first-pass metabolism that minimizes the toxicity traditionally associated with prednisone. However, some patients prefer to avoid budesonide because it still results in some corticosteroid side effects. Furthermore, budesonide treats ileal and/or right-sided colonic Crohn's disease. Therefore, alternative treatment strategies are warranted in patients with Crohn's disease.
Mesalamine had been used routinely for decades in patients with Crohn's disease in clinical practice. More recently, it has fallen out of favor owing to meta-analyses that did not show a favorable benefit. 9 We demonstrated that mesalamine at doses above 2.4 g/d was more effective than placebo for the induction of remission of Crohn's disease. This finding was shown in the NMA but not in the traditional meta-analysis. Although the data for mesalamine were not as strong as for budesonide or corticosteroids, our study results suggest that it may still be considered as a therapeutic alternative in patients who prefer to avoid steroids.
The effectiveness of mesalamine in our NMA conflicts with previous meta-analyses and with current clinical practice guidelines. 5 The result of the NMA is dependent on the assumptions made in selection of studies for pooling, the definition of variables, and the outcomes used in analyses. For example, a previous NMA defined remission based on CDAI, Harvey Bradshaw Index, or by the author, whereas we minimized the heterogeneity between RCTs by a priori analyzing only RCTs that strictly evaluated the induction of remission as defined by a CDAI ,150. 9 Another potential source of bias is disease activity at study enrollment. Mesalamine, sulfasalazine, and budesonide have been indicated for the treatment of mild or mild-to-moderate Crohn's disease. However, the definition of mild-moderate Crohn's disease varied broadly between most RCTs, whereas others did not restrict disease activity at enrollment. Because of the variability of disease activity at study enrollment, our NMA and previous pooled studies have evaluated a heterogeneous definition of "mild-to-moderate" Crohn's disease. We performed a sensitivity analysis that restricted the definition of disease activity at enrollment to a CDAI from 150 to 450, which demonstrated that only high-dose mesalamine, high-dose budesonide, and corticosteroids were superior to placebo (see Appendix enrollment CDAI between 150 and 450 represents a broad spectrum of disease activity and does not account for the history of Crohn's disease before enrollment into an RCT, such as previous inflammatory bowel disease medications, complications, or intestinal resections. These factors would favor the effectiveness of prednisone over budesonide or mesalamine. By contrast, sulfasalazine was not shown to be superior to placebo or other comparator agents. Only 2 RCTs for sulfasalazine met our inclusion criteria, which reduced the precision of evaluating sulfasalazine in the NMA. In our primary analysis, sulfasalazine had an 87% probability of being superior to placebo. The results of our NMA are consistent with a recent traditional meta-analysis that reported "a nonsignificant trend in favor of sulfasalazine over placebo for inducing remission in Crohn's disease. 37 Several limitations associated with NMAs should be considered. Because head-to-head trials were lacking, the precision of this study was reduced. Also, an NMA does not control for effect modifiers across studies; this is particularly relevant to studies in Crohn's disease where a number of factors may influence the outcomes, including disease severity at enrollment, disease location, concomitant medications, and previous intestinal resections. Budesonide and different formulations of mesalamine are designed to target specific regions of the small bowel and colon; however, because of a paucity of RCTs comparing the efficacy of treatments stratified by disease location, a sensitivity analysis could not be performed. Doses of drugs included in an NMA will influence the results presented. In the sensitivity analysis that stratified the dosing of mesalamine to correspond to the thresholds used by a previous NMA, we still observed different results (see Appendix Table 4 , Supplemental Digital Content 1, http://links.lww.com/IBD/B451). The inconsistent results could be due to our definition of remission and the incorporation of sulfasalazine and corticosteroids, which statistically alters the comparisons and the precision of the CrIs. Further, sensitivity analyses that remove sulfasalazine and corticosteroids retain the consistency of the findings for high-dose budesonide, but not for mesalamine (see Appendix Table 7 , Supplemental Digital Content 1, http://links.lww.com/IBD/B451). Finally, the external validity of our findings only relates to the enrolled study populations of the RCTs and, thus, may not be generalizable to all phenotypes of Crohn's disease.
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